Related Experiment Video

Updated: Apr 26, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K

Latest pharmacotherapy options for treating hepatitis C in HIV-infected patients

Juan Macías1, Karin Neukam, Nicolás Merchante

  • 1Hospital Universitario de Valme, Unit of Infectious Diseases and Microbiology , Avda. de Bellavista. 41014 Sevilla , Spain +34 955015684 ; +34 955315795 ; japineda@telefonica.net.

Expert Opinion on Pharmacotherapy
|August 3, 2014
PubMed

Insights

Directly acting antiviral drugs (DAA) offer high cure rates for Hepatitis C virus (HCV) in patients coinfected with HIV. Newer DAA regimens are effective, though cost may impact accessibility.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV)/HIV coinfection accelerates liver disease progression.
  • Sustained virological response (SVR) to pegylated interferon plus ribavirin is low in coinfected patients.
  • Directly acting antiviral drugs (DAA) have transformed HCV treatment.

Purpose of the Study:

  • To review DAA therapies in advanced development for HIV/HCV coinfection.
  • To identify Phase III clinical trials of DAAs in this patient subset.

Main Methods:

  • Searched clinicaltrials.gov for Phase III DAA trials including HIV/HCV-coinfected patients.
  • Summarized data on DAA development in HIV/HCV coinfection.

Main Results:

  • High SVR rates are achievable with current DAA regimens in HIV/HCV coinfection.
  • Next-generation DAAs address limitations of earlier DAA treatments.
  • All-oral DAA regimens show promise for ideal HCV therapy in coinfected individuals.

Conclusions:

  • HCV cure is highly achievable in HIV-coinfected patients using available DAAs.
  • Next-generation DAAs improve upon first-generation DAA limitations.
  • High cost of newer DAAs may restrict patient access to effective HCV treatment.
Abstract

Keywords:
HIVdirect-acting antiviral drughepatitis C virustreatment

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
42.8K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
380
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
56
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271